Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

European Journal of Pharmacology

Volumn 318, Issue 2-3, 1996, Pages 429-435

  Knudsen, Lotte Bjerre ^a   Pridal, Lone ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

GLP 1 (glucagon like peptide 1); GLP 1 (7 34); GLP 1 (7 35); GLP 1 (7 36) amide; GLP 1 (9 36) amide; Metabolite; Receptor activation; Receptor binding

Indexed keywords

ADENYLATE CYCLASE; DRUG METABOLITE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL STRAIN BHK; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MALE; NONHUMAN; PANCREAS; PLASMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; PANCREAS; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; RECEPTORS, GLUCAGON;

EID: 0030607672     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00795-9     Document Type: Article

References (25)

1. Adelhorst, K., B.B. Hedegaard, L.B. Knudsen and O. Kirk, 1994, Structure-activity studies of GLP-1, J. Biol. Chem. 269, 6275.
2. Cottrell, D., R. Gelfand, S. Cataland, T. O'Dorisio, C. Casey and K. Osei, 1992, Insulinotropic effect of GLP-1-(7-37) in non-insulin dependent diabetes mellitus patients: a study of dose and glucose dependency, Clin. Res. 40, 734A.
3. Deacon, C.F., A.H. Johnsen and J.J. Holst, 1995a, Degradation of GLP-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo, J. Clin. Endocrinol. Metab. 80, 952.
4. Deacon, C.F., M.A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms and J.J. Holst, 1995b, Both subcutaneous and intravenously administered GLP-1 are rapidly degraded from the N-terminus in type-2 diabetic patients and in healthy subjects, Diabetes 44, 1126.
5. Drejer, K., V. Kruse, U.D. Larsen, P. Hougaard, S. Bjørn and S. Gammeltoft, 1991, Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells, Diabetes 40, 1588.
6. Elliot, R.M., L.M. Morgan, J.A. Tredger, S. Deacon, J. Wright and V. Marks, 1993, GLP-1-(7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretionresponse to nutrient ingestion in man: Acute post-prandial and 24-h secretion pattern, J. Endocrinol. 138, 179.
7. Frohman, L.A., T.R. Downs, E.P. Heimer and A.M. Feli, 1989, Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma, J. Clin. Invest. 83, 1533.
8. Gallwitz, B., M. Witt, G. Paetzold, C. Morys-Wortman, B. Zimmermann, K. Eckart, U.R. Fölsch and W.E. Schmidt, 1994, Structure-activity characterization of glucagon-like peptide-1, Eur. J. Biochem. 225, 1151.
9. Gallwitz, B., M. Witt, G. Paetzold, C. Morys-Wortman, U.R. Fölsch and W.E. Schmidt, 1995, Binding characteristics of N-terminal GIP/GLP-1 hybrid peptides, Endocrinol. Metab. 2, 39.
10. Gefel, D., G.K. Hendrick, S. Mojsov, J.F. Habener and G.C. Weir, 1990, GLP-1 analogs: effects on insulin secretion and cAMP formation, Endocrinology 126, 2164.
11. Grandt, D., B. Sieberg, J. Sievert, M. Schimiezek, U. Becker, G. Holtmann, P. Layer, J.R. Reeve, Jr., V.E. Eysselein, H. Goebell and M. Müller, 1994, Is GLP-1-(9-36) amide an endogenous antagonist at GLP-1 receptors?, Digestion 55, 302.
12. Gutniak, M.D, C. Ørskov, J.J. Holst, B. Ahrén and S. Efendic, 1992, Antidiabetic effect of GLP-1-(7-36) amide in normal subjects and patients with diabetes mellitus, New Engl. J. Med. 326, 1316.
13. Hvidberg, A., M.T. Nielsen, J. Hilsted, C. Ørskov and J.J. Holst, 1994, Effect of GLP-1 on hepatic glucose production in healthy man, Metabolism 43, 104.
14. Jornvall, H., M. Carlquist, S. Kwauk, S.C. Otte, C.H. McIntosh, J.C. Brown and W. Mutt, 1981, Amino acid sequence and heterogeneity of gastric inhibitory polypeptide, FEBS Lett. 123, 205.
15. Mentlein, R., B. Gallwitz and W.E. Schmidt, 1993, DPP IV hydrolyses gastric inhibitory peptide, GLP-1-(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum, Eur. J. Biochem. 215, 829.
16. Mojsov, S., 1992, Structural requirements for biological activity of GLP-1, Int. J. Pept. Protein Res. 40, 333.
17. Nauck, M.A., N. Kleine, C. Ørskov, J.J. Holst, B. Willms and W. Creutzfeldt, 1993, Normalization of fasting hyperglycemia by exogenous GLP-1-(7-36) amide in type 2 diabetic patients, Diabetologia 36, 741.
18. Pridal, L., S.H. Ingwersen, F.S. Larsen, J.J. Holst, K. Adelhorst and O. Kirk, 1995, Comparison of sandwich ELISA and RIA for detection of exogenous GLP-1-(7-36) amide in plasma, J. Pharm. Biomed. Anal. 13, 841.
19. Pridal, L, C.F. Deacon, O. Kirk, J.V. Christensen, R.D. Carr and J.J. Holst, 1996, Glucagon-like peptide-1-(7-37) has a larger volume of distribution than glucagon-like peptide-1-(7-36) amide in dogs and is degraded more quickly in vitro by dog plasma, Eur. J. Drug Metab. Pharmacokin. 21, 51.
20. Robberecht, P., P. De Neef, M. Waelbroeck, J.-C. Camus, J.-L. Scemema, D. Fourmy, M. Pradayrol, N. Vaysse and J. Christophe, 1988, Secretin receptors in human pancreatic membranes, Pancreas 3, 529.
21. Rorstad, O.P., I. Wanke, D.H. Coy, A. Fournier and M. Huang, 1990, Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide, Mol. Pharmacol. 37, 971.
22. Schmidt, W.E., E.G. Siegel, B. Gallwitz, H. Kümmel, R. Ebert and W. Creutzfeldt, 1986, Characterization of the insulinotropic activity of fragments derived from gastric inhibitory polypeptide, Diabetologia 29, 59IA.
23. Suzuki, S., K. Kawai, S. Ohashi, H. Mukai and K. Yamashita, 1989, Comparison of the effects of various C-terminal and N-terminal fragment peptides of GLP-1 on insulin and glucagon release from isolated rat pancreas, Endocrinology 125, 3109.
24. Thorell, J.F. and B.G. Johansson, 1971, Enzymatic iodination of polypeptide with (125I) to high specific activity, Biochim. Biophys. Acta 251, 363.
25. Unson, C.G., D. Andreu, E.M. Gurzenda and R.B. Merrifield, 1987, Synthetic peptide antagonists of glucagon, Proc. Natl. Acad. Sci. USA 84, 4083.